Skip to contentI
Integra Lifesciences Holdings Corp
I
IARTIntegra Lifesciences Holdings Corp Source filing unavailable
Q3 2012 · —
Revenue$210.08M$210.08M+3.9% vs Q3 2011 Net Income$13.21M$13.21M+17.5% vs Q3 2011 EPS Diluted$0.46$0.46+17.9% vs Q3 2011 Gross Profit$130,536,000+5.7% Operating Income$19,736,000+7.9% Operating Cash Flowderived
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Integra Lifesciences Holdings Corp · CIK 917520 · Engraved from SEC EDGAR
$27,909,000
+17.3%
Free Cash Flowderived$8,192,000−29.1% Margins · derivedGross margin62.1%+1.0 pt vs Q3 2011
Operating margin9.4%+0.3 pt vs Q3 2011
Net margin6.3%+0.7 pt vs Q3 2011